Pub Date : 2019-11-25DOI: 10.3760/CMA.J.ISSN.2095-2848.2019.11.007
Junyu Tong, Tingting Qiao, Zhongwei Lyu
Objective To analyze the expression and clinical significance of solute carrier family 5 member 5 (SLC5A5), the coding gene of sodium/iodide symporter (NIS), in thyroid carcinoma. Methods The messenger RNA (mRNA) expression of SLC5A5 in thyroid carcinoma and normal thyroid tissues from The Cancer Genome Atlas (TCGA) was compared using independent-sample t test and results were shown in one scatter plot. The relation between clinical features of thyroid carcinoma and the changes of SLC5A5 mRNA was analyzed on LinkedOmics using Kruskal-Wallis test or Wilcoxon test. Results Data from TCGA showed that the SLC5A5 mRNA expression in thyroid carcinoma (1.419±0.049) was significantly reduced compared with that in normal thyroid tissues (3.301±0.087; t=12.66, P<0.01). The expression of SLC5A5 mRNA in thyroid carcinoma is affected by ethnicity (χ2=0.300, P<0.05). Moreover, the expression of SLC5A5 mRNA were decreased with the increase of pathologic grading (Ⅰ, Ⅱ, Ⅲ, Ⅳ) and T, N, M stages (χ2 values: 0.114, 0.215, z values: -0.345, -0.102, all P<0.05). Conclusions The expression level of SLC5A5 mRNA is associated with clinical characteristic of thyroid carcinoma. SLC5A5 mRNA has the potential to become one candidate biomarker to assess disease and predict the development of thyroid carcinoma. Key words: Thyroid neoplasms; Sodium/iodide symporter; Gene expression; Databases, nucleic acid
{"title":"Expression and clinical significance of SLC5A5 gene of sodium/iodide symporter in thyroid carcinoma based on the biological information database","authors":"Junyu Tong, Tingting Qiao, Zhongwei Lyu","doi":"10.3760/CMA.J.ISSN.2095-2848.2019.11.007","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.2095-2848.2019.11.007","url":null,"abstract":"Objective \u0000To analyze the expression and clinical significance of solute carrier family 5 member 5 (SLC5A5), the coding gene of sodium/iodide symporter (NIS), in thyroid carcinoma. \u0000 \u0000 \u0000Methods \u0000The messenger RNA (mRNA) expression of SLC5A5 in thyroid carcinoma and normal thyroid tissues from The Cancer Genome Atlas (TCGA) was compared using independent-sample t test and results were shown in one scatter plot. The relation between clinical features of thyroid carcinoma and the changes of SLC5A5 mRNA was analyzed on LinkedOmics using Kruskal-Wallis test or Wilcoxon test. \u0000 \u0000 \u0000Results \u0000Data from TCGA showed that the SLC5A5 mRNA expression in thyroid carcinoma (1.419±0.049) was significantly reduced compared with that in normal thyroid tissues (3.301±0.087; t=12.66, P<0.01). The expression of SLC5A5 mRNA in thyroid carcinoma is affected by ethnicity (χ2=0.300, P<0.05). Moreover, the expression of SLC5A5 mRNA were decreased with the increase of pathologic grading (Ⅰ, Ⅱ, Ⅲ, Ⅳ) and T, N, M stages (χ2 values: 0.114, 0.215, z values: -0.345, -0.102, all P<0.05). \u0000 \u0000 \u0000Conclusions \u0000The expression level of SLC5A5 mRNA is associated with clinical characteristic of thyroid carcinoma. SLC5A5 mRNA has the potential to become one candidate biomarker to assess disease and predict the development of thyroid carcinoma. \u0000 \u0000 \u0000Key words: \u0000Thyroid neoplasms; Sodium/iodide symporter; Gene expression; Databases, nucleic acid","PeriodicalId":10099,"journal":{"name":"Chinese Journal of Nuclear Medicine and Molecular Imaging","volume":"39 1","pages":"670-674"},"PeriodicalIF":0.0,"publicationDate":"2019-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45039560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-11-25DOI: 10.3760/CMA.J.ISSN.2095-2848.2019.11.009
Zhao Yanjun, T. Ping, Ni Jianming
{"title":"99Tcm-MDP SPECT/CT imaging in osteopoikilosis with bone metastases: a case report","authors":"Zhao Yanjun, T. Ping, Ni Jianming","doi":"10.3760/CMA.J.ISSN.2095-2848.2019.11.009","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.2095-2848.2019.11.009","url":null,"abstract":"","PeriodicalId":10099,"journal":{"name":"中华核医学与分子影像杂志","volume":"39 1","pages":"678-679"},"PeriodicalIF":0.0,"publicationDate":"2019-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45281242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-11-25DOI: 10.3760/CMA.J.ISSN.2095-2848.2019.11.006
Lulu Zhang, Fan Qiu, Pengjun Zhang, Zhihong Xu, Ting Bu, S. Zang, Shuyue Ai, Feng Wang
Objective To synthesis 177Lu-prostate specific membrane antigen (PSMA)-I&T with automated module, evaluate the biodistribution and pharmacokinetics in mice and study the targeting property in human prostate cancer cell line LNCaP Clone FGC. Methods The iQS-TS automated module was applied in labeling 177Lu-PSMA-I&T. Radiochemical purity and stability were determined with high performance liquid chromatography (HPLC). The biodistribution was observed in normal ICR mice and U-SPECT/CT imaging was performed in LNCaP Clone FGC tumor-bearing mice. Independent-sample t test was used to analyze the data. Results 177Lu-PSMA-I&T was stable in vitro and in vivo, with the radiolabeled yield of (91.5±4.9)% and radiochemical purity >99%. The half maximal inhibitory concentration (IC50) of 177Lu-PSMA-I&T binding to LNCaP Clone FGC cells was (26.74±3.53) nmol/L. The uptake of 177Lu-PSMA-I&T by LNCaP Clone FGC cells increased with time and significantly decreased after the inhibitor addition (t values: 4.301-27.483, all P<0.05). 177Lu-PSMA-I&T was cleared from blood rapidly and predominantly excreted by kidneys. Significant radioactive uptake was observed in tumors with a long retention time. Conclusion 177Lu-PSMA-I&T can be produced in a convenient and efficient procedure using iQS-TS automated module, with good biological properties and excellent affinity and targeting property towards prostate cancer cells, which making it a potential radiopharmaceutical for prostate cancer therapy. Key words: Prostatic neoplasms; Prostate-specific membrane antigen; Isotope labeling; Lutetium; Chemical synthesis; Tumor cells, cultured; Mice, nude
{"title":"177Lu-PSMA-I&T automated radiolabeling and preclinical prostate cancer targeting research","authors":"Lulu Zhang, Fan Qiu, Pengjun Zhang, Zhihong Xu, Ting Bu, S. Zang, Shuyue Ai, Feng Wang","doi":"10.3760/CMA.J.ISSN.2095-2848.2019.11.006","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.2095-2848.2019.11.006","url":null,"abstract":"Objective \u0000To synthesis 177Lu-prostate specific membrane antigen (PSMA)-I&T with automated module, evaluate the biodistribution and pharmacokinetics in mice and study the targeting property in human prostate cancer cell line LNCaP Clone FGC. \u0000 \u0000 \u0000Methods \u0000The iQS-TS automated module was applied in labeling 177Lu-PSMA-I&T. Radiochemical purity and stability were determined with high performance liquid chromatography (HPLC). The biodistribution was observed in normal ICR mice and U-SPECT/CT imaging was performed in LNCaP Clone FGC tumor-bearing mice. Independent-sample t test was used to analyze the data. \u0000 \u0000 \u0000Results \u0000177Lu-PSMA-I&T was stable in vitro and in vivo, with the radiolabeled yield of (91.5±4.9)% and radiochemical purity >99%. The half maximal inhibitory concentration (IC50) of 177Lu-PSMA-I&T binding to LNCaP Clone FGC cells was (26.74±3.53) nmol/L. The uptake of 177Lu-PSMA-I&T by LNCaP Clone FGC cells increased with time and significantly decreased after the inhibitor addition (t values: 4.301-27.483, all P<0.05). 177Lu-PSMA-I&T was cleared from blood rapidly and predominantly excreted by kidneys. Significant radioactive uptake was observed in tumors with a long retention time. \u0000 \u0000 \u0000Conclusion \u0000177Lu-PSMA-I&T can be produced in a convenient and efficient procedure using iQS-TS automated module, with good biological properties and excellent affinity and targeting property towards prostate cancer cells, which making it a potential radiopharmaceutical for prostate cancer therapy. \u0000 \u0000 \u0000Key words: \u0000Prostatic neoplasms; Prostate-specific membrane antigen; Isotope labeling; Lutetium; Chemical synthesis; Tumor cells, cultured; Mice, nude","PeriodicalId":10099,"journal":{"name":"Chinese Journal of Nuclear Medicine and Molecular Imaging","volume":"39 1","pages":"665-669"},"PeriodicalIF":0.0,"publicationDate":"2019-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43409049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-11-25DOI: 10.3760/CMA.J.ISSN.2095-2848.2019.11.001
Yufan Zhang, Jianjing Liu, Xiaofeng Li
Objective To explore the predictive value of 18F-fluorodeoxyglucose (FDG) PET conventional parameters and radiomics features for human epidermal growth factor receptor 2 (HER2) expression which was uncertain by immunohistochemistry (IHC) detection in invasive breast cancer. Methods From April 2012 to December 2017, 76 patients (all were females, age: (50.8±10.9) years) with invasive breast cancer and with uncertain HER2 expression by IHC in Tianjin Medical University Cancer Institute and Hospital were enrolled retrospectively. The 18F-FDG PET/CT images before treatment were reviewed and the expression of HER2 were confirmed by fluorescence in situ hybridization (FISH). The tumor lesions were manually outlined, and the radiomics features from PET images were extracted. Wilcoxon test was used to determine whether there was difference in PET conventional metabolic parameters (maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV) and total lesion glycolysis (TLG)) and radiomics features between HER2-negative and HER2-positive groups. The receiver operating characteristic (ROC) curve analysis was used to compare the predictive efficacy of PET radiomics features for HER2 expression. Results There were 41 HER2-positive patients and 35 HER2-negative patients. No significant differences in PET conventional metabolic parameters between different HER2 expression groups were observed (U values: from -1.598 to 1.551, all P>0.05). A total of 38 PET radiomics features were extracted, and there were significant differences in gray mean, correlation, contrast, inertia, and inverse different moments between 2 groups(U values: from -2.413 to 2.527, all P<0.05). The area under the curve of the above 5 parameters for prediction of HER2 expression were 0.643, 0.638, 0.647, 0.644 and 0.643, respectively, and the contrast was the best parameter. Conclusions PET radiomics features can effectively identify HER2 expression in patients with invasive breast cancer to some extent, and the contrast may be the best. Conventional metabolic parameters have limited predictive value. Key words: Breast neoplasms; Receptor, epidermal growth factor; Immunohistochemistry; Positron-emission tomography; Tomography, X-ray computed; Deoxyglucose; Radiomics
{"title":"Predictive value of 18F-FDG PET conventional parameters and radiomics features for invasive breast cancer patients with uncertain HER2 expression by immunohistochemistry","authors":"Yufan Zhang, Jianjing Liu, Xiaofeng Li","doi":"10.3760/CMA.J.ISSN.2095-2848.2019.11.001","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.2095-2848.2019.11.001","url":null,"abstract":"Objective \u0000To explore the predictive value of 18F-fluorodeoxyglucose (FDG) PET conventional parameters and radiomics features for human epidermal growth factor receptor 2 (HER2) expression which was uncertain by immunohistochemistry (IHC) detection in invasive breast cancer. \u0000 \u0000 \u0000Methods \u0000From April 2012 to December 2017, 76 patients (all were females, age: (50.8±10.9) years) with invasive breast cancer and with uncertain HER2 expression by IHC in Tianjin Medical University Cancer Institute and Hospital were enrolled retrospectively. The 18F-FDG PET/CT images before treatment were reviewed and the expression of HER2 were confirmed by fluorescence in situ hybridization (FISH). The tumor lesions were manually outlined, and the radiomics features from PET images were extracted. Wilcoxon test was used to determine whether there was difference in PET conventional metabolic parameters (maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV) and total lesion glycolysis (TLG)) and radiomics features between HER2-negative and HER2-positive groups. The receiver operating characteristic (ROC) curve analysis was used to compare the predictive efficacy of PET radiomics features for HER2 expression. \u0000 \u0000 \u0000Results \u0000There were 41 HER2-positive patients and 35 HER2-negative patients. No significant differences in PET conventional metabolic parameters between different HER2 expression groups were observed (U values: from -1.598 to 1.551, all P>0.05). A total of 38 PET radiomics features were extracted, and there were significant differences in gray mean, correlation, contrast, inertia, and inverse different moments between 2 groups(U values: from -2.413 to 2.527, all P<0.05). The area under the curve of the above 5 parameters for prediction of HER2 expression were 0.643, 0.638, 0.647, 0.644 and 0.643, respectively, and the contrast was the best parameter. \u0000 \u0000 \u0000Conclusions \u0000PET radiomics features can effectively identify HER2 expression in patients with invasive breast cancer to some extent, and the contrast may be the best. Conventional metabolic parameters have limited predictive value. \u0000 \u0000 \u0000Key words: \u0000Breast neoplasms; Receptor, epidermal growth factor; Immunohistochemistry; Positron-emission tomography; Tomography, X-ray computed; Deoxyglucose; Radiomics","PeriodicalId":10099,"journal":{"name":"Chinese Journal of Nuclear Medicine and Molecular Imaging","volume":"39 1","pages":"641-646"},"PeriodicalIF":0.0,"publicationDate":"2019-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47775941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-11-25DOI: 10.3760/CMA.J.ISSN.2095-2848.2019.11.004
Z. Jia, R. Yan, Chang-qing Zhang, H. Zhai, Tianzheng Yang, Zhenhu Zhou
Objective To investigate the relationship between V-raf murine sarcoma viral oncogene homologue B1 (BRAF)V600E mutation and metastasis after thyroidectomy in papillary thyroid carcinoma (PTC) with different recurrence risk stratification. Methods From March 2014 to September 2017, 134 PTC patients (45 males, 89 females; age: 16-72 years) who underwent 131I treatment in the Department of Nuclear Medicine of Liaocheng People′s Hospital and had undergone BRAFV600E mutation detection were retrospectively analyzed. The recurrence risk during surgery was divided into 3 levels: low-, medium- and high-risk. Each recurrence risk group was divided into 3 subgroups according to the postoperative follow-up results: non-metastasis group, cervical lymph node metastasis group and pulmonary metastasis group. BRAFV600E mutation rates in different groups were compared (χ2 test). Results The BRAFV600E mutation rate was 55.22%(74/134) in 134 PTC patients. The mutation rates were not significantly different in the 3 metastasis subgroups for low-risk patients (n=46; χ2=2.39, P>0.05). In medium-risk patients (n=47), the mutation rate in neck lymph node metastasis group (16/19) was higher than that in pulmonary metastasis group (3/8) and non-metastasis group (25.00%, 5/20; χ2 values: 5.89 and 13.75, both P 0.05). In high risk patients (n=41), the mutation rate in neck lymph node metastasis group (85.00%, 17/20) was higher than that in the pulmonary metastasis group (5/13) and non-metastasis group (1/8; χ2 values: 7.68 and 13.08, both P 0.05). Conclusion The BRAFV600E mutation is closely related to neck lymph node metastasis after operation in middle- and high-risk patients with PTC, but it does not significantly increase the probabilities of neck lymph node metastasis in low-risk patients and pulmonary metastasis in low-, medium- and high-risk patients. Key words: Thyroid neoplasms; Neoplasms recurrence, local; Neoplasm metastasis; Proto-oncogene protein B-raf; Mutation
{"title":"Relationship between BRAFV600E mutation and metastasis after thyroidectomy in papillary thyroid carcinoma with different recurrence risk stratification","authors":"Z. Jia, R. Yan, Chang-qing Zhang, H. Zhai, Tianzheng Yang, Zhenhu Zhou","doi":"10.3760/CMA.J.ISSN.2095-2848.2019.11.004","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.2095-2848.2019.11.004","url":null,"abstract":"Objective \u0000To investigate the relationship between V-raf murine sarcoma viral oncogene homologue B1 (BRAF)V600E mutation and metastasis after thyroidectomy in papillary thyroid carcinoma (PTC) with different recurrence risk stratification. \u0000 \u0000 \u0000Methods \u0000From March 2014 to September 2017, 134 PTC patients (45 males, 89 females; age: 16-72 years) who underwent 131I treatment in the Department of Nuclear Medicine of Liaocheng People′s Hospital and had undergone BRAFV600E mutation detection were retrospectively analyzed. The recurrence risk during surgery was divided into 3 levels: low-, medium- and high-risk. Each recurrence risk group was divided into 3 subgroups according to the postoperative follow-up results: non-metastasis group, cervical lymph node metastasis group and pulmonary metastasis group. BRAFV600E mutation rates in different groups were compared (χ2 test). \u0000 \u0000 \u0000Results \u0000The BRAFV600E mutation rate was 55.22%(74/134) in 134 PTC patients. The mutation rates were not significantly different in the 3 metastasis subgroups for low-risk patients (n=46; χ2=2.39, P>0.05). In medium-risk patients (n=47), the mutation rate in neck lymph node metastasis group (16/19) was higher than that in pulmonary metastasis group (3/8) and non-metastasis group (25.00%, 5/20; χ2 values: 5.89 and 13.75, both P 0.05). In high risk patients (n=41), the mutation rate in neck lymph node metastasis group (85.00%, 17/20) was higher than that in the pulmonary metastasis group (5/13) and non-metastasis group (1/8; χ2 values: 7.68 and 13.08, both P 0.05). \u0000 \u0000 \u0000Conclusion \u0000The BRAFV600E mutation is closely related to neck lymph node metastasis after operation in middle- and high-risk patients with PTC, but it does not significantly increase the probabilities of neck lymph node metastasis in low-risk patients and pulmonary metastasis in low-, medium- and high-risk patients. \u0000 \u0000 \u0000Key words: \u0000Thyroid neoplasms; Neoplasms recurrence, local; Neoplasm metastasis; Proto-oncogene protein B-raf; Mutation","PeriodicalId":10099,"journal":{"name":"Chinese Journal of Nuclear Medicine and Molecular Imaging","volume":"39 1","pages":"657-660"},"PeriodicalIF":0.0,"publicationDate":"2019-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48583611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-11-25DOI: 10.3760/CMA.J.ISSN.2095-2848.2019.11.013
Minghao Wu, Yanyan Zhang, Lin Cao, Xuening Zhang
Tumor neovascularization plays an important role in the occurrence, development and metastasis of cancer. Non-invasive quantification and detection of tumor neovascularization is crucial for early diagnosis and prognosis assessment of cancer. Targeted molecular imaging has arisen in vascular targeting imaging and precise treatment based on the molecular characteristics of neovascularization. Aminopeptidase N (APN, or CD13) is a multifunctional membrane-bound exopeptidase that is overexpressed in neovascular endothelial cells and some tumor cells but rarely expressed in normal blood vessels, which makes it a potential target for tumor neovascularization imaging and anti-angiogenic therapy. This review summarizes the application progress and the future development trend of target molecular imaging and precise treatment based on CD13. Key words: Neoplasms; Neovascularization, pathologic; Angiogenesis inhibitors; Antigens, CD13; Trends
{"title":"Research progress of CD13-targeted molecular probe in tumor neovascularization imaging and therapy","authors":"Minghao Wu, Yanyan Zhang, Lin Cao, Xuening Zhang","doi":"10.3760/CMA.J.ISSN.2095-2848.2019.11.013","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.2095-2848.2019.11.013","url":null,"abstract":"Tumor neovascularization plays an important role in the occurrence, development and metastasis of cancer. Non-invasive quantification and detection of tumor neovascularization is crucial for early diagnosis and prognosis assessment of cancer. Targeted molecular imaging has arisen in vascular targeting imaging and precise treatment based on the molecular characteristics of neovascularization. Aminopeptidase N (APN, or CD13) is a multifunctional membrane-bound exopeptidase that is overexpressed in neovascular endothelial cells and some tumor cells but rarely expressed in normal blood vessels, which makes it a potential target for tumor neovascularization imaging and anti-angiogenic therapy. This review summarizes the application progress and the future development trend of target molecular imaging and precise treatment based on CD13. \u0000 \u0000 \u0000Key words: \u0000Neoplasms; Neovascularization, pathologic; Angiogenesis inhibitors; Antigens, CD13; Trends","PeriodicalId":10099,"journal":{"name":"中华核医学与分子影像杂志","volume":"39 1","pages":"688-693"},"PeriodicalIF":0.0,"publicationDate":"2019-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44506903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-11-25DOI: 10.3760/CMA.J.ISSN.2095-2848.2019.11.011
Q. Pan
{"title":"99Tcm-MDP bone scintigraphy in Charcot joint: a case report","authors":"Q. Pan","doi":"10.3760/CMA.J.ISSN.2095-2848.2019.11.011","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.2095-2848.2019.11.011","url":null,"abstract":"","PeriodicalId":10099,"journal":{"name":"中华核医学与分子影像杂志","volume":"39 1","pages":"682-684"},"PeriodicalIF":0.0,"publicationDate":"2019-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46249346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-11-25DOI: 10.3760/CMA.J.ISSN.2095-2848.2019.11.008
Fang Lei, An Jianping, Zhao Hui, Mao Junfeng, Yao Changshuai, Zhang Feng-ping
{"title":"MRI and PET/CT imaging in plasmacytoma of spine: two case reports","authors":"Fang Lei, An Jianping, Zhao Hui, Mao Junfeng, Yao Changshuai, Zhang Feng-ping","doi":"10.3760/CMA.J.ISSN.2095-2848.2019.11.008","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.2095-2848.2019.11.008","url":null,"abstract":"","PeriodicalId":10099,"journal":{"name":"中华核医学与分子影像杂志","volume":"39 1","pages":"675-677"},"PeriodicalIF":0.0,"publicationDate":"2019-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42028491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-11-25DOI: 10.3760/CMA.J.ISSN.2095-2848.2019.11.005
Xian-min Ding, Ying Ding, Sen Wang, Guang Yang, Fu-qiang Zhang, Deyu Li, Qiang Li, Wen-liang Li
Objective To investigate the clinical value of pre-ablation stimulated thyroglobulin (psTg) in the prediction of metastasis of differentiated thyroid carcinoma (DTC) in children and adolescents. Methods The study included 51 children and adolescent patients (20 males, 31 females, age: 8-18(13.5±3.0) years) with DTC who had undergone total thyroidectomy and lymphadenectomy and were going to have the first 131I ablation therapy from March 2012 to December 2017 in the Affiliated Cancer Hospital of Zhengzhou University. Patients′ serum thyroglobulin antibody (TgAb) levels were normal. They were divided into M0 group (without metastasis) and M1 group (with metastasis). The psTg difference between the two groups was compared using Mann-Whitney U test. The receiver operating characteristic (ROC) curves and diagnostic critical point (DCP) of psTg for the metastasis prediction were analyzed. Results The psTg levels of M0 group (n=20) and M1 group (n=31) were 5.76(3.38, 18.51) μg/L and 280.46(37.66, 470.00) μg/L, respectively, and the difference between the two groups was statistically significant (U=41, P<0.05). The area under the ROC curve of psTg was 0.934 (95% CI: 0.869-0.999) with the sensitivity, specificity and accuracy of 80.6%(25/31), 100%(20/20) and 88.2%(45/51) respectively, with the DCP value of 31.98 μg/L. Conclusion The psTg value detected before the first 131I treatment has an important predictive value for postoperative metastasis of DTC in children and adolescents. Key words: Thyroid neoplasms; Neoplasm metastasis; Thyroglobulin; Radiotherapy; Iodine radioisotopes; Child; Adolescent
{"title":"Predictive value of stimulated thyroglobulin before the first 131I ablation for metastasis of differentiated thyroid carcinoma in children and adolescents","authors":"Xian-min Ding, Ying Ding, Sen Wang, Guang Yang, Fu-qiang Zhang, Deyu Li, Qiang Li, Wen-liang Li","doi":"10.3760/CMA.J.ISSN.2095-2848.2019.11.005","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.2095-2848.2019.11.005","url":null,"abstract":"Objective \u0000To investigate the clinical value of pre-ablation stimulated thyroglobulin (psTg) in the prediction of metastasis of differentiated thyroid carcinoma (DTC) in children and adolescents. \u0000 \u0000 \u0000Methods \u0000The study included 51 children and adolescent patients (20 males, 31 females, age: 8-18(13.5±3.0) years) with DTC who had undergone total thyroidectomy and lymphadenectomy and were going to have the first 131I ablation therapy from March 2012 to December 2017 in the Affiliated Cancer Hospital of Zhengzhou University. Patients′ serum thyroglobulin antibody (TgAb) levels were normal. They were divided into M0 group (without metastasis) and M1 group (with metastasis). The psTg difference between the two groups was compared using Mann-Whitney U test. The receiver operating characteristic (ROC) curves and diagnostic critical point (DCP) of psTg for the metastasis prediction were analyzed. \u0000 \u0000 \u0000Results \u0000The psTg levels of M0 group (n=20) and M1 group (n=31) were 5.76(3.38, 18.51) μg/L and 280.46(37.66, 470.00) μg/L, respectively, and the difference between the two groups was statistically significant (U=41, P<0.05). The area under the ROC curve of psTg was 0.934 (95% CI: 0.869-0.999) with the sensitivity, specificity and accuracy of 80.6%(25/31), 100%(20/20) and 88.2%(45/51) respectively, with the DCP value of 31.98 μg/L. \u0000 \u0000 \u0000Conclusion \u0000The psTg value detected before the first 131I treatment has an important predictive value for postoperative metastasis of DTC in children and adolescents. \u0000 \u0000 \u0000Key words: \u0000Thyroid neoplasms; Neoplasm metastasis; Thyroglobulin; Radiotherapy; Iodine radioisotopes; Child; Adolescent","PeriodicalId":10099,"journal":{"name":"中华核医学与分子影像杂志","volume":"39 1","pages":"661-664"},"PeriodicalIF":0.0,"publicationDate":"2019-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42999385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：